Function and mechanism by which interferon regulatory factor‑1 inhibits oncogenesis (Review)

Chen,Fei‑Fei; Jiang,Guan; Xu,Kerui; Zheng,Jun‑Nian

doi:10.3892/ol.2012.1051

Function and mechanism by which interferon regulatory factor‑1 inhibits oncogenesis (Review)

Authors:
- Fei‑Fei Chen
- Guan Jiang
- Kerui Xu
- Jun‑Nian Zheng
View Affiliations

Affiliations: Laboratory of Biological Cancer Therapy, Xuzhou Medical College, Jiangsu 221002, P.R. China, Department of Biology, Wake Forest University, Salem, NC 27106, USA
Published online on: November 28, 2012 https://doi.org/10.3892/ol.2012.1051
Pages: 417-423

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present review focuses on recent advances in the understanding of the molecular mechnisms by which interferon regulatory factor (IRF)‑1 inhibits oncogenesis. IRF‑1 is associated with regulation of interferon α and β transcription. In addition, numerous clinical studies have indicated that IRF‑1 gene deletion or rearrangement correlates with development of specific forms of human cancer. IRF‑1 has been revealed to exhibit marked functional diversity in the regulation of oncogenesis. IRF‑1 activates a set of target genes associated with regulation of the cell cycle, apoptosis and the immune response. The role of IRF‑1 in the regulation of various types of human tumor has important implications for understanding the susceptibility and progression of cancer. In addition, an improved understanding of the role of IRF‑1 in the pathological processes that lead to human malignant diseases may aid development of novel therapeutic strategies.

View Figures

View References

1.	Mamane Y, Heylbroeck C, Genin P, Algarte M, Servant MJ, LePage C, DeLuca C, Kwon H, Lin R and Hiscott J: Interferon regulatory factors: the next generation. Gene. 237:1–14. 1999. View Article : Google Scholar : PubMed/NCBI
2.	Taniguchi T, Ogasawara K, Takaoka A and Tanaka N: IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 19:623–655. 2001. View Article : Google Scholar : PubMed/NCBI
3.	Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM and Maniatis T: Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Mol Cell. 1:507–518. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Meraro D, Hashmueli S, Koren B, Azriel A, Oumard A, Kirchhoff S, Hauser H, Nagulapalli S, Atchison ML and Levi BZ: Protein-protein and DNA-protein interactions affect the activity of lymphoid-specific IFN regulatory factors. J Immunol. 163:6468–6478. 1999.PubMed/NCBI
5.	Lohoff M and Mak TW: Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol. 5:125–135. 2005. View Article : Google Scholar : PubMed/NCBI
6.	Nobuyuki T and Tadatsugu T: The interferon regulatory factors and oncogenesis. Semin Cancer Biol. 10:73–81. 2000. View Article : Google Scholar
7.	Fujita T, Sakakibara J, Sudo Y, Miyamoto M, Kimura Y and Taniguchi T: Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J. 7:3397–3405. 1988.
8.	Mamane Y, Grandvaux N, Hernandez E, Sharma S and Innocente SA: Repression of IRF-4 target genes in human T cell leukemia virus-1 infection. Oncogene. 21:6751–6765. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Xu DS, Zhao LJ, Valle LD, Miklossy J and Zhang LW: Interferon regulatory factor 4 is involved in Epstein-Barr Virus-mediated transformation of human B lymphocytes. J Virol. 82:6251–6258. 2008. View Article : Google Scholar : PubMed/NCBI
10.	Xu D, Meyer F, Ehlers E, Blasnitz L and Zhang L: Interferon regulatory factor 4 (IRF-4) targets IRF-5 to regulate Epstein-Barr virus transformation. J Biol Chem. 286:18261–18267. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA and Pitha PM: Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. Cancer Res. 63:6424–6431. 2003.PubMed/NCBI
12.	Deng M and Daley GQ: Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 97:3491–3497. 2001. View Article : Google Scholar : PubMed/NCBI
13.	Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan NV, Seftor RE, Wheaton WW, Amir S, Pins MR, Schutte BC and Hendrix MJ: Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem. 280:34210–34217. 2005. View Article : Google Scholar
14.	Zhao Y, Xu DS, Jiang YJ and Zhang LW: Dual functions of interferon regulatory factors 7C in Epstein-Barr virus-mediated transformation of human B lymphocytes. PLoS One. 5:e94592010. View Article : Google Scholar : PubMed/NCBI
15.	Itoh S, Harada H, Nakamura Y, White R and Taniguchi T: Assignment of the human interferon regulatory factor-1 (IRF1) gene to chromosome 5q23-q31. Genomics. 10:1097–1099. 1991. View Article : Google Scholar : PubMed/NCBI
16.	Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC and List AF: Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science. 259:968–971. 1993. View Article : Google Scholar : PubMed/NCBI
17.	Ogasawara S, Tamura G, Maesawa C, Suzuki Y, Ishida K, Satoh N, Uesugi N, Saito K and Satodate R: Common deleted region on the long arm of chromosome 5 in esophageal carcinoma. Gastroenterology. 110:52–57. 1996. View Article : Google Scholar : PubMed/NCBI
18.	Tamura G, Ogasawara S, Nishizuka S, Sakata K, Maesawa C, Suzuki Y, Terashima M, Saito K and Satodate R: Two distinct regions of deletion on the long arm of chromosome 5 in differentiated adenocarcinomas of the stomach. Cancer Res. 56:612–615. 1996.PubMed/NCBI
19.	Nozawa H, Oda E, Ueda S, Tamura G, Maesawa C, Muto T, Taniguchi T and Tanaka N: Functionally inactivating point mutation in the tumor-suppressor IRF-1 gene identified in human gastric cancer. Int J Cancer. 77:522–527. 1998. View Article : Google Scholar : PubMed/NCBI
20.	Cavalli LR, Riggins RB, Wang A, Clarke R and Haddad BR: Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer. Breast Cancer Res Treat. 121:227–231. 2010. View Article : Google Scholar : PubMed/NCBI
21.	Bouker KB, Skaar TC, Harburger DS, Riggins RB, Fernandez DR, Zwart A and Clarke R: The A4396G polymorphism in interferon regulatory factor 1 is frequently expressed in breast cancer cell lines. Cancer Genet Cytogenet. 175:61–64. 2007. View Article : Google Scholar : PubMed/NCBI
22.	Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG and Martelli MF: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med. 352:254–266. 2005. View Article : Google Scholar : PubMed/NCBI
23.	Kondo T, Minamino N, Nagamura-Inoue T, Matsumoto M, Taniguchi T and Tanaka N: Identification and characterization of nucleophosmin/B23/numatrin which binds the anti-oncogenic transcription factor IRF-1 and manifests oncogenic activity. Oncogene. 15:1275–1281. 1997. View Article : Google Scholar : PubMed/NCBI
24.	Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H and Taniguchi T: Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene. 9:3313–3320. 1994.PubMed/NCBI
25.	Tzoanopoulos D, Speletas M, Arvanitidis K, Veiopoulou C, Kyriaki S, Thyphronitis G, Sideras P, Kartalis G and Ritis K: Low expression of interferon regulatory factor-1 and identification of novel exons skipping in patients with chronic myeloid leukaemia. Br J Haematol. 119:46–53. 2002. View Article : Google Scholar : PubMed/NCBI
26.	Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE and Um SJ: Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem. 275:6764–6769. 2000. View Article : Google Scholar
27.	Junsoo P, Kim K, Lee EJ, Seo YJ, Lim SN, Park K, Rho SB, Lee SH and Lee JH: Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosis. Proc Natl Acad Sci USA. 104:17028–17033. 2007. View Article : Google Scholar : PubMed/NCBI
28.	Tamura T, Yanai H, Savitsky D and Taniguchi T: The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 26:535–584. 2008. View Article : Google Scholar : PubMed/NCBI
29.	Takaoka A, Tamura T and Taniguchi T: Interferon regulatory factor family of transcription factors and regulation of oncogenesis. Cancer Sci. 99:467–478. 2008. View Article : Google Scholar : PubMed/NCBI
30.	Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW and Taniguchi T: Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell. 77:829–839. 1994. View Article : Google Scholar : PubMed/NCBI
31.	Passioura T, Dolnikov A, Shen S and Symonds G: N-ras induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res. 65:797–804. 2005.PubMed/NCBI
32.	Nozawa H, Oda E, Nakao K, Ishihara M, Ueda S, Yokochi T, Ogasawara K, Nakatsuru Y, Shimizu S, Ohira Y, Hioki K, Aizawa S, Ishikawa T, Katsuki M, Muto T, Taniguchi T and Tanaka N: Loss of transcription factor IRF-1 affects tumor susceptibility in mice carrying the Ha-ras transgene or nullizygosity for p53. Genes Dev. 13:1240–1245. 1999. View Article : Google Scholar : PubMed/NCBI
33.	Romeo G, Fiorucci G, Chiantore MV, Percario ZA, Vannucchi S and Affabris E: IRF-1 as a negative regulator of cell proliferation. J Interferon Cytokine Res. 22:39–47. 2002. View Article : Google Scholar : PubMed/NCBI
34.	Benech P, Vigneron M, Peretz D, Revel M and Chebath J: Interferon-responsive regulatory elements in the promoter of the human 2′,5′-oligo(A)synthetase gene. Mol Cell Biol. 7:4498–4504. 1987.
35.	Takikawa O, Kuroiwa T, Yamazaki F and Kido R: Mechanism of interferon-γ action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-γ and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J Biol Chem. 263:2041–2048. 1988.
36.	Kirchhoff S, Koromilas AE, Schaper F, Grashoff M, Sonenberg N and Hauser H: IRF-1 induced cell growth inhibition and interferon induction requires the activity of the protein kinase PKR. Oncogene. 11:439–445. 1995.PubMed/NCBI
37.	Pamment J, Ramsay E, Kelleher M, Dornan D and Ball KL: Regulation of the IRF-1 tumour modifier during the response to genotoxic stress involves an ATM-dependent signalling pathway. Oncogene. 21:7776–7785. 2002. View Article : Google Scholar : PubMed/NCBI
38.	Tan RS, Taniguchi T and Harada H: Identification of the lysyl oxidase gene as target of the antioncogenic transcription factor, IRF-1 and its possible role in tumor suppression. Cancer Res. 56:2417–2421. 1996.PubMed/NCBI
39.	Horiuchi M, Yamada T, Hayashida W and Dzau VJ: Interferon regulatory factor-1 up-regulates angiotensin II type 2 receptor and induces apoptosis. J Biol Chem. 272:1952–1958. 1997. View Article : Google Scholar : PubMed/NCBI
40.	Clarke N, Jimenez AM, Voltz E and Gronemeyer H: Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL. EMBO J. 23:3051–3060. 2004. View Article : Google Scholar : PubMed/NCBI
41.	Chin YE, Kitagawa M, Kuida K, Flavell RA and Fu XY: Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Mol Cell Biol. 17:5328–5337. 1997.PubMed/NCBI
42.	Sancéau J, Hiscott J, Delattre O and Wietzerbin J: IFN-beta induces serine phosphorylation of Stat-1 in Ewing’s sarcoma cells and mediates apoptosis via induction of IRF-1 and activation of caspase-7. Oncogene. 19:3372–3383. 2000.PubMed/NCBI
43.	Ruiz C, Ruiz AC, Rodriguez A, Ortiz G, Redondo JM and López A: The up-regulation of human caspase-8 by interferon-gamma in breast tumor cells requires the induction and action of the transcription factor interferon regulatory factor-1. J Biol Chem. 279:19712–19720. 2004. View Article : Google Scholar
44.	Jeay S, Pianetti S, Kagan HM and Sonenshein GE: Lysyl oxidase inhibits ras-mediated transformation by preventing activation of NF-κB. Mol Cell Biol. 23:2251–2263. 2003.PubMed/NCBI
45.	Kroger A, Dallugge A, Kirchhoff S and Hauser H: IRF-1 reverts the transformed phenotype of oncogenically transformed cells in vitro and in vivo. Oncogene. 22:1045–1056. 2003. View Article : Google Scholar : PubMed/NCBI
46.	Kroger A, Stirnweiss A, Pulverer JE, Klages, Grashoff M, Reimann J and Hauser H: Tumor suppression by IFN regulatory factor-1 is mediated by transcriptional down-regulation of cyclin D1. Cancer Res. 67:2972–2981. 2007. View Article : Google Scholar : PubMed/NCBI
47.	Pizzoferrato E, Liu Y, Gambotto A, Armstrong MJ, Stang MT, Gooding WE, Alber SM, Shand SH, Watkins SC and Storkus WJ: Ectopic expression of interferon regulatory factor-1 promotes human breast cancer cell death and results in reduced expression of survivin. Cancer Res. 64:8381–8388. 2004. View Article : Google Scholar : PubMed/NCBI
48.	Frontini M, Vijayakumar M, Garvin A and Clarke N: A ChIP-chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response. Nucleic Acids Res. 37:1073–1085. 2009. View Article : Google Scholar : PubMed/NCBI
49.	Walsh T and King MC: Ten genes for inherited breast cancer. Cancer Cell. 11:103–105. 2007. View Article : Google Scholar : PubMed/NCBI
50.	Seal S, Thompson D, Renwick A, Elliott A, Kelly P, Barfoot R, Chagtai T, Jayatilake H, Ahmed M, Spanova K, North B, McGuffog L, Evans DG, Eccles D; Breast Cancer Susceptibility Collaboration (UK); Easton DF, Stratton MR and Rahman N: Truncating mutations in the Fanconi anemia J gene BRIP1 are low penetrance breast cancer susceptibility alleles. Nat Genet. 38:1239–1241. 2006. View Article : Google Scholar : PubMed/NCBI
51.	Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M and Taniguchi T: Anti-oncogenic and oncogenic potentials of interferon regulatory factors-1 and -2. Science. 259:971–974. 1993. View Article : Google Scholar : PubMed/NCBI
52.	Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS and van Wijnen AJ: The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem. 278:26589–26596. 2003. View Article : Google Scholar : PubMed/NCBI
53.	Mori K, Yoshida K, Tani J, Nakagawa Y, Hoshikawa S and Ito S: Double-stranded RNA-induced interferon regulatory factor-1 gene expression in FRTL-5 rat thyroid cells. Mol Cell Endocrinol. 84:77–86. 2001. View Article : Google Scholar : PubMed/NCBI
54.	Wang J, Zhang WJ, Zhang YS, Chen Y, Zou B, Jiang B, Pang R, Gu Q, Qiao L, Lan HY, Kung HF and Wong BC: c-Jun N-terminal kinase (JNK1) upregulates XIAP-associated factor 1 (XAF1) through interferon regulatory factor 1 (IRF-1) in gastrointestinal cancer. Carcinogenesis. 30:222–229. 2009. View Article : Google Scholar : PubMed/NCBI
55.	Nguyen H, Lin R and Hiscott J: Activation of multiple growth regulatory genes following inducible expression of IRF-1 or IRF/RelA fusion proteins. Oncogene. 15:1425–1435. 1997. View Article : Google Scholar : PubMed/NCBI
56.	Savitsky D, Tamura T, Yanai H and Taniguchi T: Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 59:489–510. 2010. View Article : Google Scholar : PubMed/NCBI
57.	Strasser A, Harris AW, Jacks T and Cory S: DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell. 79:329–339. 1994. View Article : Google Scholar : PubMed/NCBI
58.	Tamura T, Ishihara M, Lamphier MS, Tanaka N, Oishi I, Aizawa S, Matsuyama T, Mak TW, Taki S and Taniguchi T: An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. Nature. 376:596–599. 1995. View Article : Google Scholar : PubMed/NCBI
59.	Bowie ML, Ibarra C and Seewalt VL: IRF-1 promotes apoptosis in p53-damaged basal-type human mammary epithelial cells: a model for early basal-type mammary carcinogenesis. Adv Exp Med Biol. 617:367–374. 2008. View Article : Google Scholar : PubMed/NCBI
60.	Gao J, Senthil M, Ren B, Yan J, Xing Q, Yu J, Zhang L and Yim JH: IRF-1 transcriptionally upregulates PUMA, which mediates the mitochondrial apoptotic pathway in IRF-1-induced apoptosis in cancer cells. Cell Death Differ. 17:699–709. 2009. View Article : Google Scholar : PubMed/NCBI
61.	Lallemand C, Palmieri M, Blanchard B, Meritet JF and Tovey MG: GAAP-1: a transcriptional activator of p53 and IRF-1 possesses proapoptotic activity. EMBO Rep. 3:153–158. 2002. View Article : Google Scholar : PubMed/NCBI
62.	Kim EJ, Lee JM, Namkoong SE, Um SJ and Park JS: Interferon regulatory factor-1 mediates interferon-gamma-induced apoptosis in ovarian carcinoma cells. J Cell Biochem. 85:369–380. 2002. View Article : Google Scholar : PubMed/NCBI
63.	Fulda S and Debatin KM: IFN gamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene. 21:2295–2308. 2002. View Article : Google Scholar : PubMed/NCBI
64.	Bouker KB, Skaar TC, Riggins R, Harburger DS, Fernandez DR, Zwart A, Wang A and Clarke R: Interferon regulatory factor-1 (IRF-1) exhibits tumor suppressor activities in breast cancer associated with caspase activation and induction of apoptosis. Carcinogenesis. 26:1527–1535. 2005. View Article : Google Scholar
65.	De Ambrosis A, Casciano I, Croce M, Pagnan G, Radic L, Banelli B, Di Vinci A, Allemanni G, Tonini GP, Ponzoni M, Romani M and Ferrini S: An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells. Int J Cancer. 120:39–47. 2007.PubMed/NCBI
66.	Tomita Y, Bilim V, Hara N, Kasahara T and Takahashi K: Role of IRF-1 and caspase-7 in IFN-gamma enhancement of Fas-mediated apoptosis in ACHN renal cell carcinoma cells. Int J Cancer. 104:400–408. 2003. View Article : Google Scholar : PubMed/NCBI
67.	Park SY, Seol JW, Lee YJ, Cho JH, Kang HS and Kim IS: IFN-gamma enhances TRAIL-induced apoptosis through IRF-1. Eur J Biochem. 271:4222–4228. 2004. View Article : Google Scholar : PubMed/NCBI
68.	Negishi H, Fujita Y, Yanai H, Sakaguchi S, Ouyang X, Shinohara M, Takayanagi H, Ohba Y, Taniguchi T and Honda K: Evidence for licensing of IFN-gamma-induced IFN regulatory factor 1 transcription factor by MyD88 in toll-like receptor dependent gene induction program. Proc Natl Acad Sci USA. 103:15136–15141. 2006. View Article : Google Scholar : PubMed/NCBI
69.	Taki S, Sato T, Ogasawara K, Fukuda T, Sato M, Hida S, Suzuki G, Mitsuyama M, Shin EH, Kojima S, Taniguchi T and Asano Y: Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity. 6:673–679. 1997. View Article : Google Scholar : PubMed/NCBI
70.	Trinchieri G: Biology of natural killer cells. Adv Immunol. 47:187–376. 1989. View Article : Google Scholar : PubMed/NCBI
71.	Ogasawara K, Hida S, Azimi N, Tagaya Y, Sato T, Yokochi T, Waldmann TA, Taniguchi T and Taki S: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature. 391:700–703. 1998. View Article : Google Scholar : PubMed/NCBI
72.	Gabriele L, Fragale A, Borghi P, Sestili P, Stellacci E, Venditti M, Schiavoni G, Sanchez M, Belardelli F and Battistini A: IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol. 80:1500–1511. 2006. View Article : Google Scholar : PubMed/NCBI
73.	Matsuyama T, Kimura T, Kitagawa M, Pfeffer K, Kawakami T, Watanabe N, Kundig TM, Amakawa R, Kishihara K and Wakeham A: Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell. 75:83–97. 1993. View Article : Google Scholar : PubMed/NCBI
74.	Reis LF, Ruffner H, Stark G, Aguet M and Weissmann C: Mice devoid of interferon regulatory factor 1 (IRF-1) show normal expression of type I interferon genes. EMBO J. 13:4798–4806. 1994.PubMed/NCBI
75.	White LC, Wright KL, Felix NJ, Ruffner H, Reis LF, Pine R and Ting JP: Regulation of LMP2 and TAP1 genes by IRF-1 explains the paucity of CD8 + T cells in IRF-1−/− mice. Immunity. 5:365–376. 1996.PubMed/NCBI
76.	Penninger JM, Sirard C, Mittrucker HW, Chidgey A, Kozieradzki I, Nghiem M, Hakem A, Kimura T, Timms E, Boyd R, Taniguchi T, Matsuyama T and Mak TW: The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity. 7:243–254. 1997.PubMed/NCBI
77.	Lohoff M, Ferrick D, Mittrucker HW, Duncan GS, Bischof S, Rollinghoff M and Mak TW: Interferon regulatory factor-1 is required for a T helper 1 immune response in vivo. Immunity. 6:681–689. 1997. View Article : Google Scholar : PubMed/NCBI
78.	Wiwanitkit V: Interaction between interferon regulatory factor-1 and human papillomavirus E7 oncogene in cervical cancer: an ontology study. Taiwan J Obstet Gynecol. 48:138–141. 2009. View Article : Google Scholar
79.	MacMicking J, Xie QW and Nathan C: Nitric oxide and macrophage function. Annu Rev Immunol. 15:323–350. 1997. View Article : Google Scholar : PubMed/NCBI